

# PROFOUND<sup>Medical inc.</sup>

## **1<sup>st</sup> in-human proof-of-concept study commenced at Sunnybrook Health Sciences Centre, Toronto, Canada.**

Under an independent research grant, research scientists at Sunnybrook Health Science Centre, led by Chief of Urology, Dr Laurence Klotz, MD, have successfully commenced the first in-human, proof-of-concept study for prostate cancer using their novel MRI-guided, trans-urethral ultrasound technique.

Following extensive testing of the technology in mathematical, gel, and pre-clinical models, a number of patient volunteers are participating in this study to affirm safety, accuracy and precision of the potential new treatment.

The core intellectual property from this technology has been exclusively licensed to Profound Medical Inc. of Toronto, Canada, to accelerate commercialization under the guidance of the FDA and Health Canada.

"We commend the team at Sunnybrook for their exemplary research and clinical work. It's a significant moment in the company's history, as well as potentially having a major impact on how prostate cancer patients may be treated in the next decade. We can expect to proceed as planned with human clinical feasibility trials in the USA and Canada in the near future with our medical device," stated Paul Chipperton, CEO of PMI.

**For more information about the company's activities please contact Paul Chipperton:**

T: 647 291 8545

E: [pchipperton@profoundmedical.com](mailto:pchipperton@profoundmedical.com)